Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T14:47:32.671Z.
Calculation as of: 2026-10-06T14:47:32.671Z.
Quote observation: 2026-10-06T14:45:13.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 19f1946388931e4ee5326c5171249fc23a65b0c9e42408d49e268755c1a57655
PE RATIO
N/A
Market Cap
$978.16M
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Kura Oncology, Inc. (KURA) | $929.47M | N/A | N/A | N/A | N/A |
| CeriBell, Inc. (CBLL)vs › | $929.91M | N/A | N/A | N/A | N/A |
| MoonLake Immunotherapeutics (MLTX)vs › | $926.10M | N/A | N/A | N/A | N/A |
| Odyssey Therapeutics, Inc. (ODTX)vs › | $924.60M | N/A | N/A | N/A | N/A |
| HealthStream, Inc. (HSTM)vs › | $915.75M | 43.82 | 37.03 | 45.62 | 62.08 |
| Bioventus Inc. (BVS)vs › | $894.80M | 17.15 | 40.25 | 40.25 | 34.02 |
| Arbutus Biopharma Corp (ABUS)vs › | $887.93M | 5.76 | 5.80 | 5.80 | 5.80 |
| LB Pharmaceuticals Inc Common Stock (LBRX)vs › | $978.16M | N/A | N/A | N/A | N/A |
| MeiraGTx Holdings plc (MGTX)vs › | $979.81M | 14.90 | 18.35 | 18.35 | 18.35 |
| Aktis Oncology, Inc. (AKTS)vs › | $986.27M | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$10.47
Forward EPS (Est.)
$-3.22
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
